Artwork

Content provided by Berkeley Talks and UC Berkeley. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Berkeley Talks and UC Berkeley or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The future of psychedelic science

1:02:14
 
Share
 

Manage episode 413370500 series 2530675
Content provided by Berkeley Talks and UC Berkeley. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Berkeley Talks and UC Berkeley or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In Berkeley Talks episode 195, UC Berkeley professors discuss how and why psychedelic substances first evolved, the effects they have in the human brain and mind, and the mechanism behind their potential therapeutic role.

"If it's true that the therapeutic effects are in part because we're returning to this state of susceptibility, and vulnerability, and ability to learn from our environment similar to childhood," says psychology Professor Gül Dölen, "then if we just focus on the day of the trip and don't instead also focus our therapeutic efforts on those weeks after, where the critical period is presumably still open, then we're missing the opportunity to really integrate those insights that happen during the trip into the rest of the network of memories that are supporting those learned behaviors.

"And then the caution is that we don't want to be opening up these critical periods and then, for example, returning people to a traumatic environment or exposing them to potentially bad actors … So we want to be very careful about the way that we take care of patients after they've been in this open state of the critical period."

Panelists of this March 27, 2024 event included:

  • Imran Khan (moderator): Executive director of the Berkeley Center for the Science of Psychedelics (BCSP).
  • Gül Dölen: Renee & U.S. Marine Lance Cpl. Bob Parsons Endowed Chair in psychology, psychedelics, and neuroscience; professor in the Department of Psychology.
  • Daniela Kaufer: Professor in the Department of Integrative Biology and in the Helen Wills Neuroscience Institute; associate dean of biological sciences.
  • Noah Whiteman: Professor of integrative biology and of molecular and cell biology; faculty director of the Essig Museum of Entomology.
  • Michael Silver: Professor in the Herbert Wertheim School of Optometry and Vision Science and in the Helen Wills Neuroscience Institute; faculty director of BCSP.

Listen to the episode and read the transcript on Berkeley News (news.berkeley.edu/podcasts).

Music by Blue Dot Sessions.

UC Berkeley photo of Daniela Kaufer.



Hosted on Acast. See acast.com/privacy for more information.

  continue reading

208 episodes

Artwork

The future of psychedelic science

Berkeley Talks

21 subscribers

published

iconShare
 
Manage episode 413370500 series 2530675
Content provided by Berkeley Talks and UC Berkeley. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Berkeley Talks and UC Berkeley or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In Berkeley Talks episode 195, UC Berkeley professors discuss how and why psychedelic substances first evolved, the effects they have in the human brain and mind, and the mechanism behind their potential therapeutic role.

"If it's true that the therapeutic effects are in part because we're returning to this state of susceptibility, and vulnerability, and ability to learn from our environment similar to childhood," says psychology Professor Gül Dölen, "then if we just focus on the day of the trip and don't instead also focus our therapeutic efforts on those weeks after, where the critical period is presumably still open, then we're missing the opportunity to really integrate those insights that happen during the trip into the rest of the network of memories that are supporting those learned behaviors.

"And then the caution is that we don't want to be opening up these critical periods and then, for example, returning people to a traumatic environment or exposing them to potentially bad actors … So we want to be very careful about the way that we take care of patients after they've been in this open state of the critical period."

Panelists of this March 27, 2024 event included:

  • Imran Khan (moderator): Executive director of the Berkeley Center for the Science of Psychedelics (BCSP).
  • Gül Dölen: Renee & U.S. Marine Lance Cpl. Bob Parsons Endowed Chair in psychology, psychedelics, and neuroscience; professor in the Department of Psychology.
  • Daniela Kaufer: Professor in the Department of Integrative Biology and in the Helen Wills Neuroscience Institute; associate dean of biological sciences.
  • Noah Whiteman: Professor of integrative biology and of molecular and cell biology; faculty director of the Essig Museum of Entomology.
  • Michael Silver: Professor in the Herbert Wertheim School of Optometry and Vision Science and in the Helen Wills Neuroscience Institute; faculty director of BCSP.

Listen to the episode and read the transcript on Berkeley News (news.berkeley.edu/podcasts).

Music by Blue Dot Sessions.

UC Berkeley photo of Daniela Kaufer.



Hosted on Acast. See acast.com/privacy for more information.

  continue reading

208 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide